- Synthesis and crystal structure of metal-organic frameworks [Ln2(pydc-3,5)3(H2O)9]n 3nH2O (Ln = Sm, Eu, Gd, Dy; pydc-3,5 = pyridine-3,5-dicarboxylate) along with the photoluminescent property of its europium one
-
Rare-earth metal-organic frameworks, [Ln2(pydc)3(H2O)9] n3nH2O (Ln = Sm, Eu, Gd, Dy; pydc = pyridine-3,5-dicarboxylate), were synthesized and characterized by elemental analysis, IR spectra and single-crystal X-ray diffraction. The solid-state photoluminescence measurements exhibited red light-emitting characteristic of europium (III) coordination polymer. The title compounds consist of one-dimensional dual chains, in which each metal atom is nine-coordinated with oxygen atoms.
- Shi, Qisong,Zhang, Shu,Wang, Qian,Ma, Hongwei,Yang, Guoqiang,Sun, Wen-Hua
-
-
Read Online
- Self-assembly of bis-β-diketone-based [M2 L 2] dinuclear platforms into 2-dimensional coordination polymers
-
A bis-β-diketone ligand incorporating a 3,5-substituted pyridine ring between its two β-diketone domains (1,1′-(pyridine-3,5-diyl)bis(4,4-dimethylpentane-1,3-dione), H2L1) and its interaction with three divalent cations (Cu2+, Zn2+ and Pd2+) is reported. Charge neutral dinuclear metallocycles of type [M2L12] were obtained in each case and their X-ray structures determined. [Pd2L12] incorporates two square-planar O4-coordinated metal centres. The zinc(ii) and copper(ii) complexes contain five-coordinate O4N1-metal centres in which the pyridyl nitrogen from adjacent [M2L12] metallocycles coordinates apically forming two-dimensional coordination polymers of type {[Zn2L12]n(dmf)n} and {[Cu2L12]n(dmf)n}. Desolvation of the coordination polymers led to loss of crystallinity.
- Brock,McMurtrie, John C.,Clegg
-
p. 4786 - 4791
(2019/08/20)
-
- DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS
-
The disclosure is directed to novel dopamine D3 receptor antagonists, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, including treating drug dependency and psychosis.
- -
-
Page/Page column 150
(2016/05/19)
-
- On the formation of niacin (vitamin B3) and pyridine carboxylic acids in interstellar model ices
-
The formation of pyridine carboxylic acids in interstellar ice grains was simulated by electron exposures of binary pyridine (C5H5N)-carbon dioxide (CO2) ice mixtures at 10 K under contamination-free ultrahigh vacuum condi
- McMurtry, Brandon M.,Turner, Andrew M.,Saito, Sean E.J.,Kaiser, Ralf I.
-
p. 173 - 184
(2016/06/13)
-
- Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
-
This invention provides a combination, comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof. This invention also provides a method of treating a disease that is responsive to inhibition of MMP-13 and cyclooxygenase-2, comprising administering to a patient suffering from such a disease the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof. This invention also provides a pharmaceutical composition, comprising the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient. The invention combination may also be further combined with other pharmaceutical agents depending on the disease being treated.
- -
-
-
- Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib
-
This invention provides a combination, comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with a selective inhibitor of COX-2, or a pharmaceutically acceptable salt thereof, that is not celecoxib or valdecoxib. This invention also provides a method of treating a disease that is responsive to inhibition of MMP-13 and cyclooxygenase-2, comprising administering to a patient suffering from such a disease the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with a selective inhibitor of COX-2, or a pharmaceutically acceptable salt thereof, that is not celecoxib or valdecoxib. This invention also provides a pharmaceutical composition, comprising the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with a selective inhibitor of COX-2, or a pharmaceutically acceptable salt thereof, that is not celecoxib or valdecoxib, and a pharmaceutically acceptable carrier, diluent, or excipient. This invention also provides a combination comprising an NSAID, or a pharmaceutically acceptable salt thereof, and an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof. This invention also provides a pharmaceutical composition, comprising the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with an NSAID, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient. This invention also provides a method of treating a disease that is responsive to inhibition of MMP-13 and cyclooxygenase-1 or cyclooxygenase-2, comprising administering to a patient suffering from such a disease the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with an NSAID, or a pharmaceutically acceptable salt thereof. The invention combinations may also be further combined with other pharmaceutical agents depending on the disease being treated.
- -
-
-
- PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS
-
Selective MMP-13 inhibitors are pyridine derivatives of the formula or a pharmaceutically acceptable salt thereof, wherein: R1 and R2 independently are hydrogen, halo, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, NO 2, NR4R5, CN, or CF3, E is independently O or S; A and B independently are OR4 or NR4R5; R4 and R5 independently are H. C1-C 6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, (CH2)n aryl, (CH 2)n cycloalkyl, (CH2)n heteroaryl, or R4 and R5 when taken together with the nitrogen to which they are attached complete a 3 to 8-membered ring containing carbon atoms and optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted, n is an integer of from 0 to 6.
- -
-
-
- Substituted pyridine compounds
-
Disclosed herein are herbicidal pyridine compounds substituted at the 2- or 6-position with an OR2 moiety where R2 is hydrogen, lower alkyl, halomethyl, lower cyanoalkyl, alkenyl or alkynyl, as well as herbicidal compositions and herbicidal use of these compounds.
- -
-
-
- Penta-substituted pyridine compounds, herbicidal compositions and herbicidal method of use
-
Disclosed herein are herbicidal pyridine compounds substituted at the 3- and/or 5-position with a carboxylic acid-derived heterocyclic moiety, as well as herbicidal compositions and use of these compounds.
- -
-
-
- Primary 2H Kinetic Isotope Effects in the Base-catalysed 1,3-Prototropic Rearrangement of 1-Methylindene and 1,3-Dimethylindene
-
Rate constants and primary deuterium kinetic isotope effects (p. d. k. i. e. s.) have been determined for the base-catalysed rearrangement of 1-methylindene (1) and 1,3-dimethylindene (3) in the solvent o-dichloropbenzene at 30 deg C.The structurally similar tertiary amines 1-aza-adamantane, quinuclidine, 1,3-diaza-adamantane, DABCO, and 1,3,5-triaza-adamantane were used as catalysts.Substrate (3) gave a lower isotope effect than (1).The response in p. d. k. i. e.. due to a change in basicity of the amine catalyst is very similar for (1) and (3).Despite its intermediate basicity, DABCO showed a significantly lower p. d. k. i. e. for both substrates.The p. d. k. i. e. s. obtained for the other bases, with a pK at or around 2.6, were almost constant.The consequences of a possible influence of internal ion-pair return on the rearrangement of the substrates are discussed and related to the measured p. d. k. i. e. s.The similarity between the substrates and the symmetry in the rearrangement of (3) permits some rationalizations to be made.
- Hussenius, Anita,Matsson, Olle,Bergson, Goeran
-
p. 851 - 858
(2007/10/02)
-
- A General Synthesis of Substituted Fluorenones and Azafluorenones
-
Twenty-one variously substituted fluorenones and azafluorenones have been synthesized via photochemical Pschorr cyclizations of 2-diazoniodiaryl ketones as the key ring-forming step.Direct, (bipy)3RuII-, or (bipy)3RuII/CuII-photosensitized conditions were used, depending on the system to be cyclized.Where selectivities were possible in the ring closure, the isomer ratios obtained were in accord with an aryl radical as the reactive intermediate.The precursor aminodiaryl ketones were obtained from the sequence ortho lithiation of an arylpivalamide, reaction withan aryl aldehyde to give a 2-pivalamidodiarylcarbinol, oxidation to give a 2-pivalamidodiaryl ketone, and hydrolysis to give the 2-aminodiaryl ketone.
- Kyba, Evan P.,Liu, Shiuh-Tzung,Chockalingam, Kannappan,Reddy, B. Raghava
-
p. 3513 - 3521
(2007/10/02)
-
- 1,1-Alkanediol dicarboxylate linked antibacterial agents
-
Useful antibacterial agents in which a penicillin and/or a beta-lactamase inhibitor are linked via 1,1-alkanediol dicarboxylates are of the formula STR1 where A is the residue of certain dicarboxyic acids, R3 is H or (C1 -C3), n is zero or 1 such that when n is zero R is P or B and R1 is the residue of certain esters, H or a salt thereof; and when n is 1, one of R and R1 is P and the other is B, and P is STR2 where R2 is H or certain acyl groups, and B is the residue of a beta-lactamase inhibiting carboxylic acid; a method for their use, pharmaceutical compositions thereof and intermediates useful in their production.
- -
-
-
